HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 01, January 2021 – Home-Based Diagnostic Testing: Revolutionizing IBD Treatment       » Study Reveals Understanding of China’s Carbon Emission Balance       » Developing Nanomaterials for Better Performance       » Helping Farmers Monitor Plant Health and Improve Crop Yield       » Protecting the Brain through Gut-Trained Immune Cells       » Using Machine Learning to Predict Anti-Cancer Drug Efficacy      
NEWS CRUNCH
Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
Russian biopharmaceutical company BIOCAD is the first company in the country to launch a 150-million-dollar effort to supply therapeutic products based on monoclonal antibodies to several countries outside Russia. In the end of December BIOCAD made its first shipment to Vietnam. The country received high-tech product for treatment of certain types of blood cancer. This was the first shipment under the 5-year contract with a local distributor. Previously, the Vietnamese patients could count only on the original products by Swiss global healthcare company F. Hoffmann-La Roche, but at a much higher price.

"Success of Russia's biosimilar rituximab has several ingredients. The product's high quality was proven in sizeable multinational clinical trials, yet its price is much lower than the originator's. This opened new opportunities to supply biosimilar rituximab to the patients who knew that the original product had been prohibitively expensive for them." Says BIOCAD's founder and CEO, Mr. Dmitri Morozov.

By now, BIOCAD has already signed more than a dozen agreements with the distribution and manufacturing companies in several countries of South-East Asia, such as the Philippines, Malaysia, Indonesia, and Thailand. Advanced Russian biotech products that are used for therapy of oncological and autoimmune diseases are in high demand WW. They are no inferior to the original products made by the leading Western companies, yet cost significantly less.

Source: BIOCAD
NEWS CRUNCH  
news Highlights from the E&L China 2020 Conference
news Asia’s ageing population drives development of rehabilitation technologies targeting elderly disabilities
news Virtual Expo Connect to empower access for international pharma to the world’s largest pharma ingredients market
news WEIPU, AstraZeneca, Huadong Medicine, Saint-Gobain, Baxter, Wuxi AppTec, Henlius, Medtronic and more confirmed to speak at E&L China this December
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy